ASCO Highlights Seven of 4,000 Abstracts Submitted for Annual Meeting, June 3-7
Analyzing Tumor Tissue In Clinical Trials Can Improve Outcomes, RTOG Trial Finds
Targeting One Specific Protein Can Double PFS; Triple Overall Survival
Revlimid Maintenance Therapy Delayed Progression by 90%
Drug Effectiveness Weakens After Three Years, Study Says
Nexavar Improves PFS In HER-2 Negative Breast Cancer
Xgeva Significantly Increases Bone Metastasis-Free Survival
U.S. Patients Use More Chemotherapy, Less Emergency Care than Canadians
Urocidin May Provide Alternative To Cystectomy in BCG Cancers
Clinical Trials Approved By NCI CTEP Last Month
Afinitor and Sutent Approved For Pancreatic Neuroendocrine Tumors
Abbott PCR Test For HCV Load Sensitive to Within 12 IU/mL
Trending Stories
- NIH eliminates the NCI Board of Scientific Advisors
Over its 28 year history, BSA shaped NCI-funded extramural science - Trump administration is removing the mainstays of NCI and the federal government’s cancer program
Peer review, registries, and evidence-based patient information take a big hit - Bhattacharya cancels NIH all-hands meeting
- Cyber-iconoclast Vinay Prasad named head of FDA’s CBER
An oncologist, Prasad has criticized accelerated approval, next-gen sequencing, and targeted therapies - In the Headlines: “There’s no one to stand up for NCI right now.”
- George Weiner: Cancer centers are special, as are site visits in CCSG review
